Paradigm Receives $5.75m R&D Tax Incentive Refund
Open PDF
| Stock | Paradigm Biopharmaceuticals Ltd (PAR.ASX) |
|---|---|
| Release Time | 22 Jul 2026, 8:18 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Paradigm Receives $5.75m R&D Tax Incentive Refund
Key Points
- Paradigm received $4.82m R&D Tax Incentive refund for FY25
- Additional $0.93m refund from amended FY23 income tax assessment
- Total cash receipts of $5.75m strengthen company's balance sheet
- Funds to support Phase 3 osteoarthritis clinical program
- Additional flexibility for regulatory and global partnering initiatives
Full Summary
Paradigm Biopharmaceuticals Ltd, a late-stage drug development company, announced that it has received a $4.817 million Research & Development (R&D) Tax Incentive refund for the financial year ended 30 June 2025, including interest, and a $927,317 refund from an amended FY23 income tax assessment. These cash receipts totaling approximately $5.75 million will strengthen the company's financial position and support its strategic priorities, including the progression of its Phase 3 clinical program for the treatment of knee osteoarthritis and ongoing regulatory and New Drug Application (NDA) activities.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In